From the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)
A presentation by Bayer demonstrated improvement in the treatment of non-metastatic castration-resistant prostate cancer. Separate presentations by Bristol-Myers and Janssen also demonstrated improvement in metastatic castration-resistant prostate cancer.
Non-Metastatic Castration Resistant Prostate Cancer
Results from pivotal Phase 3 ARAMIS trial with Bayer’s (BAYRY) and Orion Corporation’s jointly-developed product darolutamide plus androgen deprivation therapy (ADT) on nonmetastatic castration-resistant prostate cancer (nmCRPC) demonstrated a statistically significant improvement in metastasis-free survival (MFS) compared to placebo plus ADT . . .